Course syllabus

Due to the ongoing COVID-19 pandemic, the course will be given as a distance course with lectures and seminars via ZOOM

Drug Development BIO523/KMG046

 Programs:                  Molecular Biology and Genomics/Systems Biology programs (GU), Biotechnology program (Chalmers)

Place in program:     Year 4/5, optional

Number of students: No limitation

Course leader:           Prof. Margit Mahlapuu, Department of Chemistry and Molecular Biology (CMB), Göteborg University; Medicinaregatan 9C, 413 90 Göteborg/ Box 462  405 30 Göteborg

Phone: 0706310109

E-mail: margit.mahlapuu@gu.se

 Changes in the schedule and other messages regarding the course will be distributed through e-mail and/or posted at Canvas. Handouts and literature will likewise be available at Canvas.

Length:                       7.5 ECTS

Prerequisites:            For admission to the course, approved courses of 120 credits in the field of natural science are required, of which at least 15 credits must be within the main subject molecular biology and 15 credits in the main subject chemistry or equivalent. In addition, applicants must prove their knowledge of English.

Time:                          Fall term 2020

Aim:                            This course shall focus on a building an overall understanding of the discovery and development of novel pharmaceuticals (drug discovery/development), covering a wide spectrum of target selection, lead discovery/optimization, nonclinical in vitro/in vivo safety and efficacy studies, clinical trials, and market authorization. Examples are also given of existing drugs, how they have been developed, and their mechanisms of action. The course is mostly theoretical, but in certain parts, practical demonstrations can also be included.

Literature:                 Scientific review papers, a separate list will provided by individual lecturers via Canvas.

Exam:                         Written, at the end of the course (15 Jan 2021 13-17). Re-exam 22 Feb 2021 08-12.

Items in course:         The course is based on lectures and study visits with demonstrations. 

 Teachers:                   Margit Mahlapuu margit.mahlapuu@gu.se

                                          Per Sunnerhagen per.sunnerhagen@cmb.gu.se

                                          Marica Ericson marica.ericson@chem.gu.se

                                          Morten Grötli grotli@chem.gu.se

                                          Göran Karlsson goran.karlsson@nmr.gu.se

                                          Marc Pilon marc.pilon@cmb.gu.se

                                          Gisela Brändén gisela.branden@gu.se

                                          Björn Löwenadler bjorn.lowenadler@toleranzia.com

                                          Lorna Fletcher lorna.fletcher@ventures.gu.se

                                          Camilla Björn camilla.bjorn@ri.se

                                          Pawel Baranczewski pawel.baranczewski@farmaci.uu.se

                                          Thomas Lundbäck thomas.lundback@astrazeneca.com

                                          Joakim Håkansson joakim.hakansson@ri.se

                                          Ann-Charlotte Rosendahl ann-charlotte.rosendahl@sobrera.com

                                            Emmelie Cansby Emmelie.Cansby@gu.se

 SCHEDULE, Drug development

Premises

Lectures:                   KS31, KS32: on Chalmers main campus (Johanneberg), chemistry building (main entrance, Kemigården 4). Go straight ahead from the main entrance through the doors into the stairway and go down one level to floor 3. Enter the corridor on the north side (the side away from the main entrance) and turn right. Both rooms are equipped with projectors.      

                                      NMR Center: Swedish NMR Center in Gothenburg,             Medicinaregatan 5C. Seminar room just inside the main entrance.

                                               

Day	Times	Room	Lecture/demonstration
M 16/11	13.15 – 15.00	NA	Overview of the process of drug development (Margit Mahlapuu, CMB, GU)
	15.15 – 17.00	NA	Genetic model organisms: Yeast (Per Sunnerhagen, CMB, GU)
Th 19/11	8.00 – 9.45	NA	Transgenic mice in drug discovery and development (Margit Mahlapuu, CMB, GU)
	10.00 – 11.45	NA	Genetic model organisms: C. elegans (Marc Pilon, CMB, GU)
M 23/11	13.15 – 15.00	NA	High throughout screening: assay development, validation, and platform (Thomas Lundbäck, AstraZeneca)
Th 26/11	8.00 – 9.45	NA	Protein as a target molecule: rational drug design (Göran Karlsson, NMR center, GU)
	10.00 – 11.45	NA	Structure-based drug design using X-ray crystallography (Gisela Brändén, CMB, GU)
M 30/11	13.15 – 15.00	NA	Design of pharmaceuticals directed against proteins with known activity (Morten Grøtli, CMB, GU)
	15.15 – 17.00	NA	Advanced optical microscopy as a tool in drug development (Marica Ericson, CMB, GU)
Th 3/12	8.00 – 9.45	NA	Peptide and protein drugs (Margit Mahlapuu, CMB, GU; Björn Löwenadler, Toleranzia)
	10.00 – 11.45	NA	Medical device: differences compared to pharmaceuticals (Joakim Håkansson, RISE)
M 7/12	13.15 – 15.00	NA	Antisense and gene therapy (Emmelie Cansby, CMB, GU)
	15.15 – 17.00	NA	Development of novel anti-infectives: opportunities and vulnerabilities (Camilla Björn, RISE)
Th 10/12	8.00 – 9.45	NA	Intellectual property and financing aspects of early drug discovery (Lorna Fletcher, GU Ventures)
	10.00 – 10.45	NA	New medicines: market access and customer perspective (45 min; Ann-Charlotte Rosendahl, Sobrerea)
M 14/12	13.15 – 15.00	NA	NMR-based methods in drug discovery (Göran Karlsson, NMR center, GU)
	15.15 – 17.00	NA	Vacant
Th 17/12	8.00 – 9.45	NA	Vacant
	10.00 – 11.45	KS32	Pharmacokinetics, ADME, drug metabolism   (Pawel Baranczewski, SciLifeLab, Uppsala)
Th 19/12	9.30 – 12.00		Vacant